Short Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Rises By 46.4%

Lyell Immunopharma, Inc. (NASDAQ:LYEL) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 240,730 shares, a growth of 46.4% from the December 15th total of 164,482 shares. Currently, 1.5% of the shares of the company are short sold. Based on an average trading volume of 152,163 shares, the days-to-cover ratio is presently 1.6 days. Based on an average trading volume of 152,163 shares, the days-to-cover ratio is presently 1.6 days. Currently, 1.5% of the shares of the company are short sold.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP acquired a new position in Lyell Immunopharma during the second quarter worth about $94,000. Bridgeway Capital Management LLC acquired a new stake in Lyell Immunopharma during the second quarter worth $159,000. Clarius Group LLC boosted its holdings in Lyell Immunopharma by 4.3% during the 3rd quarter. Clarius Group LLC now owns 19,958 shares of the company’s stock valued at $324,000 after acquiring an additional 820 shares during the period. Two Sigma Investments LP grew its position in Lyell Immunopharma by 107.0% in the 3rd quarter. Two Sigma Investments LP now owns 20,827 shares of the company’s stock valued at $338,000 after acquiring an additional 10,768 shares in the last quarter. Finally, Walleye Capital LLC purchased a new stake in Lyell Immunopharma during the second quarter worth about $258,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LYEL has been the subject of several recent research reports. HC Wainwright raised Lyell Immunopharma from a “neutral” rating to a “buy” rating and boosted their price target for the company from $20.00 to $45.00 in a report on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $45.00.

Lyell Immunopharma Trading Up 3.6%

Lyell Immunopharma stock opened at $23.76 on Friday. Lyell Immunopharma has a 12-month low of $7.65 and a 12-month high of $45.00. The firm has a market capitalization of $504.66 million, a PE ratio of -1.03 and a beta of -0.13. The firm has a 50-day moving average price of $26.42 and a 200-day moving average price of $17.73.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($2.13) EPS for the quarter, beating the consensus estimate of ($2.81) by $0.68. Lyell Immunopharma had a negative net margin of 794,292.69% and a negative return on equity of 96.68%. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.01 million. As a group, sell-side analysts predict that Lyell Immunopharma will post -0.78 earnings per share for the current fiscal year.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.